FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole Co-pack for Early High-Risk Breast Cancer By Ogkologos - October 28, 2024 643 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy of ribociclib with a non-steroidal aromatase inhibitor is based on the results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Physicians Debate Recent FDA Approval of an Immune Checkpoint Inhibitor in... March 31, 2021 Olivia Newton-John Shares Positive News On Breast Cancer: “I’m Winning Over... January 28, 2020 Lorlatinib Slows Growth of ALK-Positive Lung Cancers, May Prevent Brain Metastases July 10, 2024 Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with... July 29, 2025 Load more HOT NEWS Talquetamab Continuous To Demonstrate High Overall Response Rates in Heavily Pretreated... How I Navigated the Challenges of 2 Colorectal Cancer Diagnoses As... Metastatic Colorectal Cancer May Spread Early in the Disease, Study Finds Triple Blockade Demonstrates High Response Rates in Metastatic Melanoma
